CMN 568 -Unit 3 exam study guiding
revision questions and answers
For moderate persistant asthma, symptoms occur - ANS Daily
For moderate persistant asthma, SABA use is - ANS Daily
For moderate persistant asthma, nighttime awakenings ages 0-4 - ANS 3-4 times/month
For moderate persistant asthma, nighttime awakenings for >5 - ANS > once a week, not
nightly
For moderate persistant asthma, interference with normal activity - ANS Some
For moderate persistant asthma, Lung function FEV1 or PEF (personal best), >12 - ANS
60-80&
For moderate persistant asthma, FEV1/FVC, ages 5-11 - ANS 75-80%
For moderate persistant asthma, FEV1/FVC ages over 12 - ANS less than 5%
For moderate persistant asthma, exacerbations requiring oral corticosteroids, ages 0-4 - ANS
>=2times/6 months or >= 4 wheezing episodes in a year that last longer than a day AND risk
factors for persistent asthma.
For moderate persistant asthma, exacerbations requiring oral corticosteroids, >= 5 years -
ANS >= 2 times/year of exacerbations
For moderate persistant asthma, exacerbations, recommended step for starting treatment -
ANS Step 3 and reevaluate in 2-6 weeks
After starting treatment for asthma, you should reevaluate the patient in - ANS 2-6 weeks
When is treatment not appropriate when using SABAs PRN? - ANS When more than 1
canister/month is used
Can LABAs be used as mono therapy? - ANS No, administer with ICS
What is the action of Theophylline? - ANS relaxes and opens airways, rarely used because
it requires careful monitoring
,How and why is Omalizumab given? - ANS Sub-q every 2-4 weeks; given to patients over
12 with mod to persistent asthma with positive skin test.
What is the action of ICS? - ANS prevent inflammation of the airways
What is the hallmark on CXR for miliary TB? - ANS Snowstorm
Treatment of TB in pregnancy: - ANS 2 mos: INH, RIF, EMB
7 mos: INH, RIF
What drug cannot be used in pregnancy when treating TB? - ANS PZA
Side effect of RIF? - ANS Orange secretions
SIde effect of PZA? - ANS Hyperuricemia; hepatotoxicity - (reason not given in LTBI)
Side effect of EMB: - ANS optic neuritis
Side effect of INH: - ANS Peripheral neuropathy
What drug is added to INH therapy? - ANS Vit B6
A false negative TB test can result in: - ANS malnourished, overwhelming disease, 10% of
kids
Does a negative TST exclude TB? - ANS No
You should consider COPD, and perform spirometry if any of these indicators are present in an
individual over age 40: - ANS Dyspnea (progressive, worse with exercise, persistent daily,
described as air hunger, gasping, etc), Chronic cough, chronic sputum production, and history of
exposure (tobacco smoke, occupational dusts and chemicals, smoke from home cooking and
heating fuel)
Diagnosis of COPD should be confirmed by - ANS Spirometry and clinical symptoms and
signs
Why is a low peak flow inconsistent with diagnosing COPD? - ANS poor specificity; low
peak flow can be caused by other diseases and by poor performance
What drug is contraindicated in COPD and asthma? - ANS Beta blockers
Stage III - Severe COPD has a FEV1 of - ANS FEV1<50% predicted
Stage 1 - Mild COPD has a FEV1 of - ANS FEV1> 80% predicted
,Stage 4 - Very severe COPD has a FEV1 of - ANS FEV1<30% predicted
Stage 2 - Mod COPD has a FEV1 of - ANS FEV1<80% predicted
All COPD patients have a FEV1/FEV of - ANS <70% or 0.70
When are bronchodilators prescribed in COPD? - ANS As needed to relieve intermittent or
worsening symptoms, and on a regular basis to prevent or reduce persistent symptoms
When are inhaled glucocorticoids prescribed in COPD? - ANS symptomatic patients with an
FEV1<50% predicted and repeated exacerbations.
Mild COPD treatment - ANS Flu vaccine,SABA
Mod COPD treatment - ANS Flu vaccine, SABA, LABA, Rehab
Severe COPD treatment - ANS Flu vaccine, SABA, LABA, Rehab, ICS
Very severe COPD treatment - ANS Flu vaccine, SABA, LABA, Rehab, ICS, O2 (worn 15
hrs/daily)
SABAs: - ANS Levalbuterol, Albuterol, Terbutaline, Fenoterol
LABAs: - ANS Formoterol, Salmeterol, Indacaterol, Arformoterol
Anticholinergics: - ANS Ipratropium bromide
ICS: - ANS Budenoside, Fluticasone, Beclomethasone
Systemic Glucocorticoids: - ANS Prednisone, Methylprednisolone
Characteristics of Emphysema: - ANS Usually over 50 y/o, insidious progressive dyspnea,
no cough, scant, clear sputum, hyperressonance, decreased breath sounds
Characteristics of chronic bronchitis - ANS Usually over 35 y/o, recurrent cough, PFT
normal or decreased lung capacity with residual volume, sputum is copious mucopurulent
Asthma > 12 yrs: Step 4 is treated with _____. - ANS Medium dose ICS and LABA
Asthma > 12 yrs: Step 1 is treated with ____. - ANS SABA PRN
Asthma >12 yrs: Step 3 is treated with ____. - ANS Low dose ICS and LABA or Med ICS
, Asthma >12 yrs: Step 2 is treated with _____. - ANS Low dose ICS
Asthma > 12 yrs: Step 5 is treated with ____. - ANS High dose ICS and LABA and consider
omalizumab
Asthma > 12 yrs: Step 6 is treated with____. - ANS High dose ICS and LABA and oral
corticosteroid and consider omalizumab.
What is the isoniazid chemoprophylaxis treatment if exposed to TB? - ANS 10mg/kg/d x 2
months after last contact, then Mantoux test, continue therapy for 7 months if positive.
Symptoms of active disease in TB: - ANS chronic cough, anorexia, wt loss or poor wt gain,
fever, night sweats (most children are asymptomatic)
Transmission of TB: - ANS Airborne precautions...transmitted by respiratory droplets.
For moderate persistant asthma, symptoms occur - ANS Daily
For moderate persistant asthma, SABA use is - ANS Daily
For moderate persistant asthma, nighttime awakenings ages 0-4 - ANS 3-4 times/month
For moderate persistant asthma, nighttime awakenings for >5 - ANS > once a week, not
nightly
For moderate persistant asthma, interference with normal activity - ANS Some
For moderate persistant asthma, Lung function FEV1 or PEF (personal best), >12 - ANS
60-80&
For moderate persistant asthma, FEV1/FVC, ages 5-11 - ANS 75-80%
For moderate persistant asthma, FEV1/FVC ages over 12 - ANS less than 5%
For moderate persistant asthma, exacerbations requiring oral corticosteroids, ages 0-4 - ANS
>=2times/6 months or >= 4 wheezing episodes in a year that last longer than a day AND risk
factors for persistent asthma.
For moderate persistant asthma, exacerbations requiring oral corticosteroids, >= 5 years -
ANS >= 2 times/year of exacerbations
For moderate persistant asthma, exacerbations, recommended step for starting treatment -
ANS Step 3 and reevaluate in 2-6 weeks